Search clinical trials for: GS-9450 Placebo

Total 58589 results

Gilead Sciences

Completed

Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

HCV Infection

United States, Netherlands, Germany
Gilead Sciences

Completed

Safety, Tolerability, Pharmacokinetics and Activity of GS-9450 in Adults With Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis

United States, France
Gilead Sciences

Terminated

Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

United States, United Kingdom, Germany, Canada, Puerto Rico, Poland
LivaNova

Completed

Clinical Evaluation Of The PARADYM RF Device

Heart Failure

Germany
Gilead Sciences
Ono Pharmaceutical Co. Ltd; Galapagos NV

Completed

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

Sjogren's Syndrome

United States, Spain, United Kingdom, Poland
Gilead Sciences

Active, not recruiting

Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B

Chronic Hepatitis B

Taiwan, New Zealand
Gilead Sciences

Completed

Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts

Genital Warts

United States
Gilead Sciences

Completed

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

Hepatitis C, Chronic

United States, Puerto Rico, Australia
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Combination Therapy for Chronic Hepatitis C Infection

Hepatitis C, Chronic

United States
Gilead Sciences

Completed

Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)

Lupus Membranous Nephropathy

United States
Gilead Sciences

Completed

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

Ischemic Heart Disease

United States
Gilead Sciences

Completed

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C, Chronic

United States, United Kingdom, France, Germany, Netherlands, Belgium, Austria, Poland
Gesynta Pharma AB
Ergomed

Completed

A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

Systemic Sclerosis

United Kingdom, Poland, Belgium, Netherlands
Gilead Sciences

Recruiting

Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus (MARASLE)

Rheumatoid Arthritis | Systemic Lupus Erythematosus

United States, United Kingdom, Georgia, Moldova, Republic of
Gilead Sciences

Withdrawn

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

Ischemic Heart Disease
Gilead Sciences

Withdrawn

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

Respiratory Syncytial Virus Infections

Australia
Gilead Sciences

Terminated

Study to Evaluate the Efficacy and Safety of Tilpisertib in Adults With Moderately to Severely Active Ulcerative Colitis (Falcon)

Ulcerative Colitis

United States, France, Australia, Italy, Poland, Germany, Austria, Canada, Switzerland
Gilead Sciences
Ono Pharmaceutical Co. Ltd

Completed

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

Rheumatoid Arthritis

United States
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease

Spain, United Kingdom, United States, France, Italy, Germany, New Zealand, Australia, Poland, South Africa, Hungary, Canada, Czechia
Gilead Sciences

Terminated

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy (LIBERTY-HCM)

Hypertrophic Cardiomyopathy

Australia, United States, Netherlands, Israel, Italy, France, Germany, United Kingdom
Gilead Sciences

Completed

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

Hepatitis C, Chronic

United States, Puerto Rico
Gilead Sciences

Terminated

Study of Cilofexor in Adults With Primary Sclerosing Cholangitis (PRIMIS)

Primary Sclerosing Cholangitis

United States, Belgium, Israel, Spain, United Kingdom, Australia, Germany, New Zealand, Denmark, France, Japan, Switzerland, Austria, Canada, Finland, Italy
Gilead Sciences

Completed

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

LQT2 Syndrome

United States
Gilead Sciences

Completed

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Nonalcoholic Steatohepatitis (NASH)

United States
Gilead Sciences

Terminated

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

United States, Australia, France, Poland, Ukraine, Switzerland, Romania, Canada, Netherlands, Korea, Republic of, Belgium, Russian Federation, Taiwan, New Zealand, Hungary, United Kingdom, Bulgaria, Latvia, Czechia, Slovakia, Italy and more
Gilead Sciences

Terminated

Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)

Chronic Graft Versus Host Disease

Spain, Korea, Republic of, United States, Germany, Canada, France, United Kingdom
Gilead Sciences

Terminated

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Cystic Fibrosis

France, Germany, Spain, United Kingdom, Australia
Galapagos NV
Gilead Sciences

Active, not recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis (SELECTIONLTE)

Ulcerative Colitis

United States, Netherlands, Israel, Spain, Taiwan, Australia, Italy, Hong Kong, Singapore, Korea, Republic of, Canada, Germany, United Kingdom, New Zealand, Ireland, Poland, Romania, Croatia, Belgium, Japan, India, Malaysia, Sweden, F... and more
Gilead Sciences

Terminated

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

Long QT Syndrome Type 3

United States, Germany, Canada, Netherlands, Italy, France, Israel, United Kingdom
Gilead Sciences

Completed

Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

Canada, United States, Hong Kong, United Kingdom, Switzerland, New Zealand
Galapagos NV

Terminated

A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission (CAPYBARA)

Ulcerative Colitis

United States, Germany, Korea, Republic of, Spain, France, Hungary, United Kingdom, Poland, Belgium, Czechia, Italy, South Africa, Taiwan
Gilead Sciences

Terminated

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (RAINIER)

Idiopathic Pulmonary Fibrosis

United States, Spain, Korea, Republic of, Israel, Australia, Italy, Canada, United Kingdom, Switzerland, Germany, Poland, Czechia, Belgium, France
Gilead Sciences

Completed

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

Hepatitis C, Chronic

United States, Germany
Gilead Sciences

Recruiting

Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis (PALEKONA)

Ulcerative Colitis

United States, Australia, United Kingdom, Korea, Republic of, Japan, Italy, France, Canada, Switzerland, Austria, Germany, Hungary, Poland
Galapagos NV

Recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

Axial Spondyloarthritis

Belgium, Korea, Republic of, Germany, Netherlands, France, Taiwan, Greece, United Kingdom, Italy, Bulgaria, South Africa, Estonia, Spain, Hungary, Czechia, Lithuania, Philippines, Poland, Romania, Croatia
Gilead Sciences

Recruiting

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Cutaneous Lupus Erythematosus (CLE)

United States, Spain, Czechia, Germany
Gilead Sciences

Completed

Study of Obeldesivir in Nonhospitalized Participants With COVID-19 (OAKTREE)

COVID-19

United States, Japan
Galapagos NV
Gilead Sciences

Completed

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease (DIVERSITY1)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, France, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, United Kingdom, Italy, India, Singapore, Portugal, Malaysia, New Zealand, Serbia, Ireland, Poland, Romania, Japan, ... and more
Gilead Sciences

Terminated

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness (BIRCH)

COVID-19

Spain, Japan, Korea, Republic of, Taiwan, Bulgaria, Mexico, South Africa, United Kingdom, Portugal, Romania, Hungary, Brazil, Canada, France, Italy, Poland, Singapore, Turkey
Galapagos NV
Gilead Sciences

Terminated

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease (DIVERSITYLTE)

Crohn's Disease

Hong Kong, United States, Netherlands, Belgium, Israel, Spain, Korea, Republic of, Taiwan, Germany, Australia, Italy, India, Singapore, Portugal, France, Malaysia, New Zealand, Ireland, Poland, Romania, Japan, Croatia, Iceland, United... and more
Gilead Sciences

Terminated

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

Chronic Hepatitis C

United States, Australia, Canada, New Zealand
Gilead Sciences

Recruiting

Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis (SWIFT)

Ulcerative Colitis

United States
Gilead Sciences

Terminated

Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis (PBC-Phase 2)

Primary Biliary Cholangitis

United States, Canada, Austria, United Kingdom
Gilead Sciences

Completed

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy (POLARIS-1)

Hepatitis C

United States, France, United Kingdom, Germany, Australia, Canada, New Zealand, Puerto Rico
Gilead Sciences

Completed

Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis

Hepatitis C Virus Infection

United States
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease (Divergence2)

Fistulizing Crohn's Disease

United States, Italy, Belgium, Austria, Canada, Hungary, United Kingdom, Germany, France
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Gilead Sciences
Galapagos NV

Completed

Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) (DIVERGENCE 1)

Small Bowel Crohn's Disease

United States, Belgium, United Kingdom, Germany, Spain, Czechia, Canada, Austria, France, Hungary, Italy, Ukraine
Gilead Sciences

Completed

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator (TEMPO)

Ventricular Arrhythmia

Netherlands, Israel, United States, Denmark, Canada, Germany, Czechia, Hungary, Poland

Search clinical trials for: GS-9450 Placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations